Relapsed/Refractory Patients:

Treatment Options - Treanda


Treanda® (bendamustine)

What are the key facts about Treanda?

• An intravenous chemotherapy agent.

• Approved for the treatment of myeloma in Germany and FDA-approved for the treatment of two other blood cancers.

• Shown to be effective in treating relapsed and/or refractory disease when used in combination with other myeloma therapies, including steroids, Revlimid (lenalidomide)-dex, Velcade (bortezomib), and Thalomid (thalidomide)-dex.

• Encouraging preliminary results have been seen in newly diagnosed patients when combined with melphalan and prednisone or Velcade-dex, and in combination with high-dose melphalan prior to stem cell transplantation.

What is Treanda?

Treanda (also known as bendamustine) is an intravenous chemotherapy agent. It is thought to kill tumor cells by damaging their DNA, but is also similar in structure to another class of cancer drugs and may have other anti-tumor effects.

Bendamustine is approved for the treatment of myeloma in Germany under the name Ribomustin and has been used there for many years. Treanda, made by Cephalon Oncology in the US, is currently FDA-approved for the treatment of two other blood cancers. Since Treanda is available in the US, doctors may prescribe it for other conditions, such as multiple myeloma, based on the existing data supporting its effectiveness.

The Multiple Myeloma Research Consortium (MMRC) supports the development of bendamustine in multiple myeloma in the US and is currently facilitating a trial evaluating bendamustine in combination with another myeloma agent.

What do we know about Treanda's activity in myeloma?

Much of what we know about bendamustine's activity in myeloma is from research and studies conducted in Europe. In the laboratory, bendamustine appears to be active against myeloma cells that are resistant to other agents. Benadmustine has been evaluated and used alone and in combination with other myeloma agents.

Newly Diagnosed Disease

The combination of bendamustine and prednisone was found to be more effective than the standard combination melphalan and prednisone (MP) in patients with newly diagnosed myeloma in a phase III study. Bendamustine-prednisone therapy resulted in a higher overall response rate, a significantly higher complete response rate (32% vs. 13% with MP), and a longer time to disease progression.

Treanda is being evaluated in combination with Velcade and dexamethasone (BBD) in patients who are not candidates for high-dose chemotherapy and autologous stem cell transplant. Preliminary results from this phase II trial show a high overall response rate with the three-drug combination.

Bendamustine was also added to high-dose melphalan to see if its effect on blood counts would enhance response following stem cell transplantation. Promising results without unexpected side effects were seen in a Phase I study.

Relapsed/Refractory Disease

Bendamustine has been used in Europe in relapsed/refractory disease in a number of ways, including:

  • As a single agent

  • In combination with a corticosteroid (prednisolone) and

  • In combination with Velcade or Thalomid and dexamethasone

Recent trials have demonstrated the safety and efficacy of various bendamustine combinations in relapsed and/or refractory disease. For example:

  • An analysis of French data showed that the combination of bendamustine and prednisone or dexamethasone was effective in patients with disease that was refractory to all approved myeloma drugs. Thirty percent of patients responded to therapy.

  • Treanda, Revlimid, and dexamethasone was shown to be safe and highly effective two Phase I/II trials, with overall response rates of over 50% seen.

    • In one trial, the combination was effective even in older patients up to 80 years of age, in patients who were heavily pretreated, and in patients who had previously received Revlimid. Because the regimen resulted in very low white blood cell counts, it was suggested that patients also receive a colony stimulating factor to help prevent this side effect. Researchers noted that the side effect profile of this combination makes it an attractive option for patients with pre-existing therapy-related peripheral neuropathy.

  • In a Phase II study, Treanda plus Velcade and dexamethasone was shown to be effective in patients who had received one or more prior therapies. A response rate of 68% was seen, including 21% complete responses. Low blood counts were the primary severe side effects seen.

In addition, the combination of bendamustine, Thalomid, and dexamethasone has been shown to be a useful regimen for extensively pre-treated patients with prior exposure to Velcade and Revlimid, as well as an effective and well-tolerated therapy for myeloma patients with reduced kidney function.

Treanda, alone or in combination with Revlimid-dexamethasone, is listed as a treatment option for relapsed/refractory myeloma in myeloma treatment guidelines.

How is Treanda currently being studied in myeloma?

Treanda is being evaluated in combination with Velcade-dex as initial treatment for patients who are not candidates for high-dose therapy and stem cell transplant.

Treanda is being studied in a number of trials in relapsed and/or refractory myeloma, including:

  • In combination with Revlimid and dexamethasone in a phase I/II clinical trial that is being facilitated by the MMRC. LEARN MORE »

  • In combination with Velcade in a phase II trial.

  • In combination with Velcade and Doxil (pegylated liposomal doxorubicin) in a Phase I/II trial.

  • In a Phase I/II trial in combination with Velcade, Revlimid, and dexamethasone (BVRD).

  • In combination with Pomalyst™ (pomalidomide) and dex in a Phase I/II trial.


To find a clinical trial, call 1-866-603-MMCT (-6628) or click here to go to the MMRF Patient Navigator Program.